Answers are grounded in this paper and cite their sources.
AML is a hematologic cancer that is clinically heterogeneous, with a wide range of clinical outcomes. DNA methylation changes are a hallmark of AML but are not routinely used as a criterion for risk stratification. The aim of this study was to explore DNA methylation markers that could risk stratify patients with cytogenetically normal AML (CN-AML), currently classified as intermediate-risk.
No takes yet. Share an insight, caveat, or question.
Cardoso et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: